BLA 021017 · Lilly
Humalog Mix 75/25 Pen
Insulin Lispro Protamine Recombinant, Insulin Lispro Recombinant · Injection · Insulin Analog
Last checked: Nov 19, 2026Latest source record: Jul 21, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Dec 22, 1999
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1
0 Phase 3, 0 recruiting
FAERS reports
132,953
62,518 serious, 5,883 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 16, 2026.
HUMALOG Mix75/25 is indicated to improve glycemic control in adults with diabetes mellitus. HUMALOG ® Mix75/25™ is a mixture of insulin lispro protamine, an intermediate-acting human insulin analog, and insulin lispro, a rapid-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. ( 1 ) Limitations of Use: The proportions of rapid-acting and intermediate-acting insulins are fixed and do not allow for basal versus prandial dose adjustments. ( 1 ) Limitations of Use : The proportions of rapid-acting and intermediate-acting insulins in HUMALOG Mix75/25 are fixed and do not allow for basal versus prandial dose adjustments.
Mechanism: The primary activity of insulin, including HUMALOG Mix75/25, is the regulation of glucose metabolism. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 22, 1999 Original approval · Type 3 - New Dosage Form and Type 4 - New Combination LetterReviewLabel
3 products under this application
- HUMALOG MIX 75/25 PEN · INSULIN LISPRO PROTAMINE RECOMBINANT 75 UNITS/ML; INSULIN LISPRO RECOMBINANT 25 UNITS/ML · INJECTABLE, INJECTION · Discontinued
- HUMALOG MIX 75/25 · INSULIN LISPRO PROTAMINE RECOMBINANT 75 UNITS/ML; INSULIN LISPRO RECOMBINANT 25 UNITS/ML · INJECTABLE, INJECTION · Prescription
- HUMALOG MIX 75/25 KWIKPEN · INSULIN LISPRO PROTAMINE RECOMBINANT 75 UNITS/ML; INSULIN LISPRO RECOMBINANT 25 UNITS/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Insulin Lispro Protamine Recombinant" as an intervention, any sponsor and status, largest first.
- Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic PatientsPivotal-lookingCompleted
Sun Yat-sen UniversityAcademic, hospital or other
NCT01147627 · 416 participants · Start Aug 2010 · Primary completion Aug 2012
Drug: exenatide injection; Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R and 1 more · For: Diabetes Mellitus, Type 2; Newly Diagnosed
Sites: Beijing, China; Guangzhou, China; Qingyuan, China · 25 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose increased37,220
- incorrect dose administered8,870
- blood glucose decreased8,618
- drug ineffective7,963
- visual impairment5,346
- nausea4,883
- malaise3,961
- hypoglycaemia3,846
- fatigue3,774
- drug dose omission3,675
- fall3,456
- underdose3,348
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,188 |
| 2005 | 1,273 |
| 2006 | 1,695 |
| 2007 | 1,565 |
| 2008 | 1,472 |
| 2009 | 1,807 |
| 2010 | 1,862 |
| 2011 | 2,034 |
| 2012 | 2,134 |
| 2013 | 1,766 |
| 2014 | 4,651 |
| 2015 | 28,030 |
| 2016 | 9,278 |
| 2017 | 8,866 |
| 2018 | 9,207 |
| 2019 | 9,220 |
| 2020 | 9,347 |
| 2021 | 7,818 |
| 2022 | 6,740 |
| 2023 | 5,890 |
| 2024 | 5,470 |
| 2025 | 7,844 |
| 2026 | 3,796 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Sep 1, 2026
Humalog Mix 75/25, Injection, 100 [iU]/1 mL (NDC 0002-8233-05). A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any...
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Humalog Mix 75-25 (Insulin Lispro Protamin/Lispro)
2024 spending
$14.3M
Beneficiaries
11,801
55,075 claims
Per beneficiary
$1,213
$8.07 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $89,208,218 |
| 2021 | $79,517,909 |
| 2022 | $68,003,335 |
| 2023 | $59,917,382 |
| 2024 | $14,315,749 |
Part D: Humalog Mix 75-25 Kwikpen (Insulin Lispro Protamin/Lispro)
2024 spending
$53.0M
Beneficiaries
39,245
157,545 claims
Per beneficiary
$1,351
$9.80 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $277,054,166 |
| 2021 | $250,811,374 |
| 2022 | $226,141,891 |
| 2023 | $213,875,690 |
| 2024 | $53,030,308 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Eli Lilly · Also marketed as Humalog Mix 75/25, Humalog Mix 75/25 Kwikpen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.